STUDY OF THE SEQUENTIAL ADMINISTRATION OF CARMUSTINE AND TEMOZOLOMIDE

卡莫司汀和替莫唑胺序贯给药的研究

• 批准号: 6115223
• 负责人: MICHAEL D PRADOS
• 金额: $ 5.16万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115223
• 关键词: antineoplastics; blood chemistry; carmustine; clinical research; clinical trial phase I; drug administration rate /duration; drug adverse effect; drug interactions; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; pharmacokinetics

This Phase I trial and pharmacokinetic study is to describe Temozolomide given orally on day 1 of each 6-week schedule with BCNU given either before or after the Temozolomide. To describe the different toxicities, activity and change in Temozolomide pharmacokinetics for each schedule. The GCRC will administer BCNU/ Temozolomide, draw blook for pharmacokinetic studies, do line-care teaching as needed.

这项I期试验和药代动力学研究描述了替莫唑胺口服给药，在每6周的时间表的第1天，在替莫唑胺之前或之后给予BCNU。 描述每种给药方案的不同毒性、活性和替莫唑胺药代动力学变化。 GCRC将给予BCNU/替莫唑胺，为药代动力学研究抽取血液，根据需要进行线上护理教学。